Health Affairs, 22, no. 3 (2003): 49-59 doi: 10.1377/hlthaff.22.3.49 © 2003 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Morgan, S. G. Articles by Agnew, J. D. Search for Related Content PubMed PubMed Citation Articles by Morgan, S. G. Articles by Agnew, J. D. Related Collections International Issues Pharmaceuticals Elderly

Prescription Drugs

Whither Seniors’ Pharmacare: Lessons From (And For) Canada

Canada’s provincial governments have, until relatively recently, provided virtually all seniors with generous prescription drug coverage. Managers of these programs have implemented a variety of policies to contain spending while ensuring access to necessary medicines. Some of these policies have been successful in temporarily slowing cost growth. However, the lack of comprehensive utilization management tools has resulted in ongoing spending increases that now constitute a threat to the sustainability of a public drug subsidy for Canadian seniors. Sustainable and equitable pharmacare programs require the political willingness to confront opposition to policies that will, if successful, contain program costs without obstructing access.

                      What's this?

This article has been cited by other articles:

				M. M. Mello, D. M. Studdert, and T. A. Brennan The Pharmaceutical Industry versus Medicaid -- Limits on State Initiatives to Control Prescription-Drug Costs N. Engl. J. Med., February 5, 2004; 350(6): 608 - 613. [Full Text] [PDF]